Pembrolizumab (+) Berahyaluronidase alfa
3475A-E39
Phase 2 mab active
Quick answer
Pembrolizumab (+) Berahyaluronidase alfa for Squamous Cell Carcinoma is a Phase 2 program (mab) at Merck KGaA, Darmstadt, Germany with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck KGaA, Darmstadt, Germany
- Indication
- Squamous Cell Carcinoma
- Phase
- Phase 2
- Modality
- mab
- Status
- active